全球肿瘤体内研究 (CRO) 市场规模（按地区、范围和预测）

肿瘤体内研究（CRO）的全球市场规模与预测

2024 年全球体内肿瘤学 (CRO) 市场规模价值为 20.7 亿美元，预计到 2031 年将达到 36.1 亿美元，2024 年至 2031 年的复合年增长率为 8.1%。肿瘤学体内研究和治疗均在体内进行。它涉及直接研究活体动物（例如小鼠或人类）的癌症行为、进展和对药物的反应，目的是比单纯的试管方法更准确地设计和测试新的治疗方法和干预措施。

体内肿瘤学方法对于研究癌症进展和治疗成功至关重要。活体动物模型用于评估肿瘤的发展、转移和治疗效果。这些技术将有助于开发标靶治疗方法、评估药物毒性、提高对癌症生物学的认识，所有这些都有助于推进个人化医疗并改善患者的治疗效果。

肿瘤体内研究方法有望透过更精确的肿瘤追踪、即时药物反应监测和改进的诊断影像来彻底改变个人化癌症治疗。这些技术将改善标靶治疗，减少副作用并简化早期检测，从而实现更有效和个人化的癌症治疗。

全球肿瘤体内研究 (CRO) 市场动态

影响全球癌症体内研究（CRO）市场的关键市场动态是：

主要市场驱动因子

癌症发生率上升：

癌症发生率不断上升：国际上癌症发生率呈上升趋势。这种激增促使对有效治疗和诊断技术的需求日益增长。体内模型对于药物研发和行销至关重要，并正在推动市场成长。

生物技术的进步：

生物技术的创新使得药物开发变得越来越复杂和客製化。体内模型对于评估这些创新疗法至关重要，从而推动市场成长。

增加研发投入：

製药和生技公司正在大力投资癌症研究。这些不断增加的研发成本正在产生对体内模型的需求，以帮助药物发现和开发。

监理机关核准与市场准入：

如果一种抗癌药物成功通过临床试验并获得监管部门的批准，它就可以进入市场。这些疗法的商业化通常需要使用体内模型来获得大量临床前数据，从而推动市场需求。

主要问题

成本高：

由于模型生物的成本、专用设备和员工技能等因素，开发和进行体内肿瘤学研究的成本极为昂贵。这可能会给小型生物科技公司和学术机构带来障碍。

模型限制：

虽然体内模型很有用，但它们无法完全重现人类肿瘤微环境和疾病进展。这会影响研究成果的转化相关性和药物开发的成功率。

道德考量：

在研究中使用动物会引发伦理问题。公众监督、监管障碍以及严格的伦理审查流程的需求都会增加体内研究的时间和成本。

资料标准化与共享：

研究设计、数据报告和分析的不一致导致结果难以比较和重现。制定既定协议并促进数据共享对于加速药物开发至关重要。

主要趋势：

越来越关注免疫肿瘤学：

对于研究癌症免疫反应的体内模型的需求日益增加。这一趋势是由免疫疗法的日益成功以及创新免疫药物的临床前测试的需求所推动的。

个人化医疗：

个人化医疗正在推动对病患衍生模型的需求，强调产生有效代表人类肿瘤生物学的体内模型。患者来源异种移植 (PDX) 模型越来越受欢迎，因为它们能够实现客製化的治疗方案和药物开发。

采用尖端技术：

人工智慧、机器学习和影像处理等现代技术的引入正在彻底改变体内研究。这些技术增强了数据处理能力，加快了药物研发速度，并有助于预测临床结果。

更重视法规遵循与资料完整性：

监管机构正在更详细地分析临床前数据。 CRO 和製药公司正在投资强大的品质控制系统和资料完整性实践，以确保合规性和研究结果的可信度。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况
• 市场亮点

第3章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章肿瘤体内研究 (CRO) 市场（按服务类型）

• 药物动力学研究
• 毒性测试
• 效能研究
• 生物分析与分析服务

第 5 章肿瘤体内研究 (CRO) 市场（按适应症划分）

• 实体肿瘤
• 血液系统恶性肿瘤
• 其他

第 6 章 肿瘤体内 (CRO) 市场（依最终用户）

• 製药和生技公司
• 合约研究组织 (CRO)
• 学术和研究机构
• 其他

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 对市场的影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第10章 公司简介

• Charles River Laboratories International Inc.
• Envigo CRS
• Eurofins Scientific SE
• Icon plc
• Labcorp Co. Holdings
• Medpace Holdings Inc.
• PAREXEL International Corporation
• Pharmaceutical Product Development LLC（PPD）
• Syneos Health Inc.
• WuXi AppTec Co., Ltd.

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

Global Oncology Based In Vivo (CRO) Market Size and Forecast

Global Oncology Based In Vivo (CRO) Market size was valued at USD 2.07 Billion in 2024 and is projected to reach USD 3.61 Billion by 2031 growing at a CAGR of 8.1% from 2024 to 2031. Oncology-based in vivo research or treatment occurs within a living creature. It entails researching cancer's behavior, progression and response to medicines directly in living animals, such as mice or humans, in order to design and test new treatments and interventions more accurately than in vitro approaches alone.

Oncology-based in vivo approaches are critical for investigating cancer progression and therapy success. They use live animal models to assess tumor development, metastasis and therapy response. These technologies aid in the development of targeted therapies, the assessment of drug toxicity and the knowledge of cancer biology, all of which contribute to the advancement of personalized medicine and better patient outcomes.

Oncology-based in vivo approaches will revolutionize individualized cancer treatment by allowing for more precise tumor tracking, real-time medication response monitoring and improved imaging for diagnosis. These technologies will improve targeted therapy, reduce side effects and simplify early detection, resulting in more effective and personalized cancer treatment.

Global Oncology Based In Vivo (CRO) Market Dynamics

The key market dynamics that are shaping the global oncology based in vivo (CRO) market include:

Key Market Drivers:

Increasing Cancer Prevalence:

Cancer prevalence is rising internationally. This surge increases the demand for effective therapies and diagnostic technologies. In vivo models are critical for drug discovery and development, which drives market growth.

Advances in Biotechnology:

Biotechnology innovations are enabling the development of increasingly complicated and tailored medicines. In vivo models are critical for assessing these innovative treatments and driving market growth.

Increasing R&D Investment:

Pharmaceutical and biotechnology corporations are investing considerably in cancer research. This increasing R&D spending creates a demand for in vivo models to help drug discovery and development pipelines.

Regulatory Approval and Market Entry:

Successful clinical studies and subsequent regulatory approvals for oncology treatments result in market launch. Commercialization of these medications frequently requires substantial preclinical data acquired utilizing in vivo models, thereby enhancing market demand.

Key Challenges:

High Costs:

Developing and carrying out in vivo oncology studies is exceedingly expensive because to factors such as model organism costs, specialized equipment and staff skills. This may impede smaller biotech enterprises and academic organizations.

Model Limitations:

While in vivo models are useful, they cannot fully replicate human tumor microenvironments and disease progression. This can have an impact on the translational significance of study findings and drug development success rates.

Ethical Considerations:

Using animals in research creates ethical issues. Public attention, regulatory impediments and the requirement for robust ethical review processes can all add to the time and cost of in vivo research.

Data Standardization and Sharing:

Inconsistent study design, data reporting and analysis make it difficult to compare and reproduce results. Creating established protocols and encouraging data sharing crucial for accelerating drug development.

Key Trends:

Increasing Focus on Immuno-oncology:

The demand for in vivo models to investigate immune responses to cancer is increasing. This trend is being pushed by the increasing success of immunotherapy and the necessity for preclinical testing of innovative immune-based medicines.

Personalized Medicine:

Personalized medicine is driving the demand for patient-derived models there is a rising emphasis on creating in vivo models that effectively represent human tumor biology. Patient-derived xenograft (PDX) models are gaining popularity since they enable tailored treatment options and drug development.

Adoption of Advanced Technology:

The incorporation of modern technology such as AI, machine learning and imaging is revolutionizing in vivo research. These techniques increase data processing, speed up drug discovery and help anticipate clinical outcomes.

Increasing Emphasis on Regulatory Compliance and Data Integrity:

Regulatory authorities are analyzing preclinical data more closely. CROs and pharmaceutical companies are investing in robust quality management systems and data integrity practices to ensure compliance and trust in research findings.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Oncology Based In Vivo (CRO) Market Regional Analysis

Here is a more detailed regional analysis of the global oncology based in vivo (CRO) market:

North America:

According to Verified Market Research, North America is expected to dominate the global oncology based in vivo (CRO) market.

North America is predicted to dominate the global oncology-based in vivo Contract Research Organization (CRO) market, owing to its strong healthcare infrastructure, large investment in cancer research and concentration of top pharmaceutical and biotechnology businesses.

The region's advanced technology, skilled labor and regulatory support contribute to its market supremacy. Furthermore, North America's large clinical trial networks and early adoption of novel oncology treatments add to its dominance.

As the region continues to push advances in customized medicine and targeted therapeutics, it stays at the forefront of the oncology-based in vivo CRO market, influencing worldwide trends and standards.

Asia Pacific:

According to Verified Market Research, Asia Pacific is fastest growing region in global oncology based in vivo (CRO) market.

The Asia-Pacific region is the fastest-growing market for oncology-based in vivo contract research organizations (CROs), driven by rising cancer rates and expanding healthcare infrastructure.

Rapid economic growth, increasing investment in medical research and advances in imaging and diagnostic technology are driving this expansion. Furthermore, improved regulatory conditions and an increasing emphasis on personalized treatment contribute to the region's expansion.

As more pharmaceutical and biotech businesses seek cost-effective and novel research solutions, Asia-Pacific is emerging as a key hub for oncology-based in vivo investigations, providing considerable growth and development prospects in the CRO sector.

Global Oncology Based In Vivo (CRO) Market: Segmentation Analysis

The Global Oncology Based In Vivo (CRO) Market is segmented based on Indication, Model and Geography.

Global Oncology Based In Vivo (CRO) Market, By Indication

• Blood Cancer
• Solid Tumors

Based on Indication, the Global Oncology Based In Vivo (CRO) Market is separated into Blood Cancer and Solid Tumors. Solid tumors dominate the worldwide oncology-based in vivo CRO market due to their higher occurrence and the considerable research needed for targeted medications and individualized treatments. While blood cancers are substantial, they represent a lower fraction of market activity when contrasted to the broader and more diverse research focus on solid tumors.

Global Oncology Based In Vivo (CRO) Market, By Model

• Syngeneic Model
• Xenograft

Based on Model, Global Oncology Based In Vivo (CRO) Market is divided into Syngeneic Model and Xenograft. The xenograft model presently dominates the worldwide oncology-based in vivo CRO market due to its superior capacity to imitate human tumor microenvironments. This paradigm is preferred for assessing therapeutic efficacy and mechanisms in cancer research, as it provides useful information for designing targeted therapies and individualized treatments.

Global Oncology Based In Vivo (CRO) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Oncology Based In Vivo (CRO) Market divided into North America, Europe, Asia Pacific and Rest of the World. North America leads the worldwide oncology-based in vivo CRO market due to its advanced research infrastructure, significant expenditure in cancer research and established healthcare systems. This region leads in market share and innovation, although the Asia-Pacific area is rapidly expanding and gaining prominence.

Key Players

• The Global Oncology Based In Vivo (CRO) Market study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Charles River Laboratory, ICON Plc, Thermo Fisher Scientific, Inc., Eurofins Scientific, Taconic Biosciences, Crown Bioscience, LabCorp, WuXi AppTec, EVOTEC, The Jackson Laboratory.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

• Global Oncology Based In Vivo (CRO) Market Recent Developments
• In November 2023, Crown Bioscience introduced the OrganoidXploreTM service. Our organoid panel screening tool provides rapid, reliable and clinically relevant results, accelerating preclinical research. Oncology drug discovery is changing the landscape of cancer treatment development.
• In October 2023, Coeptis Therapeutics Holdings, Inc. disclosed research on the potential of the SNAP-CAR T-cell platform to target multiple antigens. The study used SNAP-CAR technology to show its adaptive antigen-targeting capabilities in human tumor xenograft models, both in vivo and in vitro.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Oncology Based In-Vivo CRO Market, By Service Type

• Pharmacokinetic Studies
• Toxicology Testing
• Efficacy Studies
• Bioanalysis and Analytical Services

5. Oncology Based In-Vivo CRO Market, By Indication

• Solid Tumors
• Hematological Malignancies
• Others

6. Oncology Based In-Vivo CRO Market, By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Charles River Laboratories International Inc.
• Envigo CRS
• Eurofins Scientific SE
• Icon plc
• Labcorp Co. Holdings
• Medpace Holdings Inc.
• PAREXEL International Corporation
• Pharmaceutical Product Development LLC (PPD)
• Syneos Health Inc.
• WuXi AppTec Co., Ltd.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References